



Molecule of the Month

PRT-060318



PRT-060318 (also known as PRT318) was developed as an approach to heparin-induced thrombocytopenia (HIT) treatment. HIT is a major cause of morbidity and mortality which results from the associated thrombosis. PRT318 is a potent, and selective inhibitor of spleen tyrosine kinase. Inhibition of Syk minimizes HIT immune complex-induced thrombocytopenia and thrombosis *in vivo* in a transgenic mouse model.



UK Trade
& Investment



bionow[®]
MEMBER